Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin : Recommendations for Clinical Practice
© 2021 Falco et al..
Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients' quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancer management and research - 13(2021) vom: 01., Seite 6689-6703 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Falco, Agustín [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Age |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/CMAR.S322411 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330139118 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330139118 | ||
| 003 | DE-627 | ||
| 005 | 20240403233251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/CMAR.S322411 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM330139118 | ||
| 035 | |a (NLM)34471383 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Falco, Agustín |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin |b Recommendations for Clinical Practice |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Falco et al. | ||
| 520 | |a Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients' quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a age | |
| 650 | 4 | |a cisplatin | |
| 650 | 4 | |a comorbidities | |
| 650 | 4 | |a contraindication | |
| 650 | 4 | |a frailty | |
| 650 | 4 | |a toxicity | |
| 700 | 1 | |a de Oliveira, Thiago Bueno |e verfasserin |4 aut | |
| 700 | 1 | |a Cacicedo, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Ospina, Aylen Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Ticona, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Galindo, Héctor |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Marcos David |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilar-Ponce, José Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Rueda-Domínguez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Soria, Tannia |e verfasserin |4 aut | |
| 700 | 1 | |a Taberna, Miren |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias, Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Sowley, Taysser |e verfasserin |4 aut | |
| 700 | 1 | |a Mesía, Ricard |e verfasserin |4 aut | |
| 700 | 0 | |a TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer management and research |d 2009 |g 13(2021) vom: 01., Seite 6689-6703 |w (DE-627)NLM197692605 |x 1179-1322 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g day:01 |g pages:6689-6703 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/CMAR.S322411 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |b 01 |h 6689-6703 | ||